Titre
Third Proceedings of The North American Airway Collaborative (NoAAC): Consensus Statement on Trial Design for Airway Stenosis.
Type
article
Institution
UNIL/CHUV/Unisanté + institutions partenaires
Périodique
Auteur(s)
Davis, R.J.
Auteure/Auteur
Akst, L.M.
Auteure/Auteur
Allen, C.T.
Auteure/Auteur
Battafarano, R.J.
Auteure/Auteur
Born, H.L.
Auteure/Auteur
Bryson, P.C.
Auteure/Auteur
Clary, M.S.
Auteure/Auteur
Crosby, T.
Auteure/Auteur
Dhillon, V.K.
Auteure/Auteur
Dion, G.
Auteure/Auteur
Kavookjian, H.
Auteure/Auteur
Leahy, K.P.
Auteure/Auteur
Lina, I.
Auteure/Auteur
Mirza, N.
Auteure/Auteur
Morrison, R.J.
Auteure/Auteur
Motz, K.M.
Auteure/Auteur
Nelson, R.C.
Auteure/Auteur
Preciado, D.
Auteure/Auteur
Sandu, K.
Auteure/Auteur
Spiegel, J.R.
Auteure/Auteur
Walsh, J.
Auteure/Auteur
Hillel, A.T.
Auteure/Auteur
Gelbard, A.
Auteure/Auteur
Liens vers les personnes
Liens vers les unités
ISSN
2168-619X
Statut éditorial
Publié
Date de publication
2025-03-01
Volume
151
Numéro
3
Première page
263
Dernière page/numéro d’article
267
Peer-reviewed
Oui
Langue
anglais
Notes
Publication types: Journal Article ; Consensus Development Conference
Publication Status: ppublish
Publication Status: ppublish
Résumé
Airway stenosis is a rare but debilitating disorder that significantly degrades the quality of life in affected patients. Treatments are primarily surgical, and disease management lacks established medical therapies. The North American Airway Collaborative held its third symposium at The Johns Hopkins Hospital in Baltimore, Maryland, on April 15, 2024, focused on strategies to advance the care of these patients. The proceedings summarize the discussion of trial design in airway stenosis and the resulting North American Airway Collaborative consensus regarding clinical end points for rigorous study of novel therapies.
The lectures and panels centered on the translation of a growing body of preclinical data into therapeutic targets. Additionally, detailed discussion explored design of clinical trials to evaluate safety and efficacy of novel therapeutics. The need for a consensus regarding clinically meaningful end points in airway stenosis was identified to facilitate the comparison of outcomes across institutions and future multi-institutional trials.
The group achieved consensus regarding change in peak expiratory flow as the primary clinical end point in airway stenosis. Additional clinical measures, such as disease recurrence (identified as time to recurrent intervention), anatomical characterization of subglottic scar via axial computed tomography imaging, and patient-reported outcome measures (Clinical COPD Questionnaire [CCQ], Voice Handicap Index-10 [VHI-10], Eating Assessment Tool-10 [EAT-10], and 12-Item Short-Form Health Survey, version 2 [SF-12]) were identified as essential secondary outcomes.
The lectures and panels centered on the translation of a growing body of preclinical data into therapeutic targets. Additionally, detailed discussion explored design of clinical trials to evaluate safety and efficacy of novel therapeutics. The need for a consensus regarding clinically meaningful end points in airway stenosis was identified to facilitate the comparison of outcomes across institutions and future multi-institutional trials.
The group achieved consensus regarding change in peak expiratory flow as the primary clinical end point in airway stenosis. Additional clinical measures, such as disease recurrence (identified as time to recurrent intervention), anatomical characterization of subglottic scar via axial computed tomography imaging, and patient-reported outcome measures (Clinical COPD Questionnaire [CCQ], Voice Handicap Index-10 [VHI-10], Eating Assessment Tool-10 [EAT-10], and 12-Item Short-Form Health Survey, version 2 [SF-12]) were identified as essential secondary outcomes.
PID Serval
serval:BIB_973063A7AF14
PMID
Date de création
2025-01-27T10:41:57.198Z
Date de création dans IRIS
2025-05-21T02:43:00Z